Kymera's Sold Million Stock: Insider Move or Signal Ahead
Kymera’s CEO recently monetized a sizable stake after a strong run. This article unpacks the insider sale, what kymer...
Uncover the best no annual fee rewards card for your needs. Our guide helps you navigate options to enhance your spending benefits.
23,410 articlesKymera’s CEO recently monetized a sizable stake after a strong run. This article unpacks the insider sale, what kymer...
Outside money from AIPAC-backed groups totals nearly $30 million in Michigan's Senate primary, testing how much influ...
Investors flocked to Ferroglobe after a midweek earnings update, turning a measured bounce into a genuine momentum pl...
When a blue-chip pharma stock falls 25%, many investors wonder if it's time to buy. This guide breaks down how to ass...
A Knoxville hospital will be renamed in Dolly Parton’s honor as her philanthropy inspires new literacy efforts at hom...
Gevo's 2025 earnings story hinges on SAF production, licensing deals, and cost management. This article breaks down t...
ResMed stock often sits on the radar, but three solid factors suggest it deserves closer attention. This practical gu...
The administration targets a $1.6 trillion tariff-revenue gap with a broader, slower path for tariffs that invites mo...
Oil breaks through $119 as geopolitical risk spikes. This article explains why this nuclear energy stock may stand ou...
A billionaire’s offer to cover federal salaries sparked headlines—and a real lesson in personal finance. This guide e...
The AI boom isn’t over yet, according to seasoned investor Paul Tudor Jones Says. This piece breaks down why the rall...
The (onon) 2026 earnings call offers critical clues about growth drivers, margin reset, and next steps for investors....